. Author manuscript; available in PMC: 2010 Mar 1.

Published in final edited form as: Sleep Med. 2008 May 14;10(3):319–328. doi: 10.1016/j.sleep.2008.02.001

Table 4.

Polysomnographic and Actigraphic Sleep Outcomes^†

	Sleep Latency (minutes)	WASO (minutes)	Sleep Efficiency (%)
Polysomnography^‡

Baseline	19.7 (21.5)	121.8 (54.2)	68.1 (12.2)
Single Night
Valerian	12.6 (6.1)	122.6 (66.4)	67.4 (15.2)
Placebo	14.4 (10.9)	139.9 (65.2)	66.5 (15.8)
Two-weeks
Valerian	20.3 (15.8)	139.5 (60.4)	65.7 (13.8)
Placebo	15.6 (9.8)	128.6 (61.0)	68.1 (11.1)

Actigraphy^‡

First Week
Valerian	NA	47.1 (16.8)	83.9 (6.7)
Placebo		47.9 (15.7)	84.0 (5.7)
Second Week
Valerian	NA	53.8 (24.3)	83.4 (5.6)
Placebo		48.6 (22.4)	84.4 (4.6)

^†

Wilcoxon signed-ranks, two-sided, were used to evaluate the primary outcome valerian versus placebo, all p > .05.

^‡

Polysomnography: baseline = mean of Night 1 and Night 2, single night = Night 3/31 only, two-week dose = mean of the last two dosing nights (Nights 15 & 16/Nights 43 & 44). Actigraphy: baseline = mean of last five screening nights, first week = mean of the first five home nights (Nights 4-8/Nights 32-36), and second week = mean of the last five home nights (Nights 10-14/Nights 38-42).